SPARC2024-10-012024-12-31 SPARC2024-10-012024-12-31 SPARC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SPARC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member SPARC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member SPARC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SPARC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member SPARC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member SPARC2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532872 SPARC NA Sun Pharma Advanced Research Company Limited Equity 2024-04-01 2025-03-31 2025-02-10 2025-01-31 INR Lakhs Third quarter 18:30:00 19:45:00 2025-02-10 2025-02-10 Not applicable Single segment Pharmaceutical Research and Development 2024-10-01 2024-12-31 Unaudited Consolidated 149100000.00 1900000.00 151000000.00 45800000.00 0.00 0.00 309900000.00 28000000.00 31400000.00 530300000.00 945400000.00 -794400000.00 0.00 -794400000.00 700000.00 0.00 700000.00 0.00 -795100000.00 0.00 0.00 0.00 0.00 -795100000.00 1000000.00 -794100000.00 0.00 0.00 0.00 0.00 324500000.00 1 -2.45 -2.45 0.00 0.00 -2.45 -2.45 1. These unaudited consolidated financial results relate to Sun Pharma Advanced Research Company Limited (the 'Company') and its Wholly Owned Subsidiary (together the ‘Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements . 2. The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 10, 2025. 3. The above unaudited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 4.The Group has incurred cash losses in past quarters and in the current quarter. The Group has a support letter from its promoter group entity basis which its status as Going Concern continues. 5.The Group decided to close the study relating to Parkinson Disease programme (K0706) following results of the PROSEEK trial. The Group is in the process of determining necessary costs for project closure and has made a provision amounting to `1,100 lakhs in the current quarter. 6.The Group has only one reportable business segment namely 'Pharmaceutical Research and Development'. 7. Previous period figures have been regrouped / reclassified, wherever considered necessary. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 445800000.00 17900000.00 463700000.00 174200000.00 0.00 0.00 1237300000.00 45000000.00 94400000.00 1823900000.00 3374800000.00 -2911100000.00 0.00 -2911100000.00 6300000.00 0.00 6300000.00 0.00 -2917400000.00 0.00 0.00 0.00 0.00 -2917400000.00 2000000.00 -2915400000.00 0.00 0.00 0.00 0.00 324500000.00 1 -8.71 -8.71 0.00 0.00 -8.71 -8.71 Clinical trial expenses / products development expense 257800000.00 Other expenses 113700000.00 Professional charges 158800000.00 Clinical trial expenses / products development expense 698500000.00 Other expenses 439100000.00 Professional charges 686300000.00 -500000.00 -1400000.00 -500000.00 -600000.00